The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects (HYCA)
Primary Purpose
Hypertension
Status
Unknown status
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Sodium nitrite
Sodium chloride
Sponsored by

About this trial
This is an interventional basic science trial for Hypertension
Eligibility Criteria
Inclusion Criteria (subjects with hypertension):
- BMI 18.5-30.0
- Ambulatory daytime blood pressure >135 mmHg systolic and/or >85 mmHg diastolic
- Women of childbearing potential must use safe contraception
Exclusion Criteria (subjects with hypertension):
- Tobacco smoking, medicine or substance abuse
- Weekly consumption of more than 14 units (12 g alcohol per unit) for women and 21 units for men
- Pregnancy or nursing
- Neoplasia
- Clinically significant heart, lung, liver, kidney, metabolic or neurologic disease
- Albuminuria > 300 mg/L
- Renography with signs of renal artery stenosis or hydronephrosis
- Clinically signs of secondary hypertension
- Clinically significant hypokalemia
- Clinically significant anemia
- Estimated glomerular filtration rate (eGFR) < 60 ml/min
- Clinically significant findings in screening blood samples, urine sample or ECG
- Persistent office blood pressure > 170/105 mmHg on the maximum dose of amlodipine (10 mg daily)
- Unacceptable symptoms of elevated blood pressure
- Unacceptable side effects of amlodipine
Inclusion Criteria (healthy normotensive subjects):
- BMI 18.5-30.0
- Women of childbearing potential must use safe contraception
Exclusion Criteria (healthy normotensive subjects):
- Tobacco smoking, medicine or substance abuse
- Weekly consumption of more than 14 units (12 g alcohol per unit) for women and 21 units for men
- Medical treatment 2 weeks prior to each examination day, except for contraception
- Pregnancy or nursing
- Neoplasia
- Clinically significant heart, lung, liver, kidney, metabolic or neurologic disease
- Clinically significant albuminuria
- Clinically significant anemia
- Estimated glomerular filtration rate (eGFR) < 60 ml/min
- Clinically significant findings in screening blood samples, urine sample or ECG
- Ambulatory daytime blood pressure >135/85 mmHg
- Blood donation within 1 month of the first examination day
Sites / Locations
- Department of Medical Research and Medicine, Holstebro Regional HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Sodium nitrite
Placebo
Arm Description
Sodium nitrite, 240 micrograms/kg/hour for 2 hours
Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
Outcomes
Primary Outcome Measures
Fractional urinary sodium excretion (FENa)
Secondary Outcome Measures
Peripheral (brachial) blood pressure
Measured by oscillometric sphygmomanometer
Central aortic systolic blood pressure (CASP)
Measured by tonometric pulse wave analysis. Device BPro from HealthSTATS international, Singapore
Plasma concentration of nitrite and nitrate (NOx)
Urinary excretion of nitrite and nitrate (NOx)
Glomerular filtration rate
Proximal sodium transport (Estimated by lithium clearance)
Estimated by lithium clearance
Free water clearance
Urinary excretion of cyclic guanosine monophosphate (cGMP)
Urinary excretion of epithelial sodium channels (ENaC)
Urinary excretion of aquaporin 2 water channels (AQP2)
Plasma concentration of renin (PRC)
Plasma concentration of angiotensin II (ANG2)
Plasma concentration of aldosterone
Plasma concentration of atrial natriuretic peptide (ANP)
Plasma concentration of brain natriuretic peptide (BNP)
Plasma concentration of cyclic guanosine monophosphate (cGMP)
Plasma concentration of endothelin
Plasma concentration of vasopressin (AVP, ADH)
Full Information
NCT ID
NCT02527837
First Posted
February 18, 2015
Last Updated
August 17, 2015
Sponsor
Erling Bjerregaard Pedersen
1. Study Identification
Unique Protocol Identification Number
NCT02527837
Brief Title
The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects
Acronym
HYCA
Official Title
The Effect of Sodium Nitrite Infusion on Renal Variables, Peripheral and Central Blood Pressure in Hypertensive Versus Normotensive Subjects in a Randomised, Placebo Controlled, Cross Over, Case-control Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
October 2016 (Anticipated)
Study Completion Date
October 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Erling Bjerregaard Pedersen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate how the effect of infused sodium nitrite differs in hypertensives compared to healthy age and sex matched controls. The effects on renal handling of nitrite, nitrate, sodium and water, plasma concentrations of vasoactive hormones, peripheral (brachial) and central blood pressure will be evaluated.
Detailed Description
Nitric oxide (NO) is an important vasodilating molecule with a very complex biochemistry and metabolism. NO is classically synthesized from L-arginin by endothelial nitric oxide synthase (eNOS) located in the endothelial cell lining. Several chronic cardiovascular diseases such as hypertension, chronic kidney disease and diabetes are accompanied by endothelial dysfunction and hence diminished synthesis of NO. NO is a very reactive molecule and direct investigation of its function are limited and it has mainly been investigated by inhibition of eNOS. Recent research has shown that sodium nitrite is readily converted to NO by enzymes in vivo. The effects of sodium nitrite on renal variables, vasoactive hormones and central blood pressure are previously unexamined. It is now possible to achieve serial estimations of the central aortic systolic pressure (CASP) by a wrist born device.
Hypothesis:
Sodium nitrite infusion increases the urinary sodium excretion and glomerular filtration rate (GFR)
Sodium nitrite infusion increases plasma levels of nitrite, nitrate, NO and cyclic guanosine monophosphate (cGMP)
Sodium nitrite infusion lowers the peripheral and central blood pressure
Renal clearance of nitrite is constant and not dose dependent
Sodium nitrite infusion affects vasoactive hormones
The hemodynamic and renal effects is more pronounced in hypertensives as compared to healthy controls.
Purpose:
The purpose of this study is to investigate the effects of sodium nitrite infusion on
Renal handling of nitrite, nitrate, sodium and water
Plasma concentrations of vasoactive hormones
Peripheral (brachial) blood pressure and CASP
Design:
15 hypertensive subjects and 15 healthy, age and sex matched controls is recruited. Each subject will attend to two examination days. Four days prior to each examination day subjects are given a standardized diet with a low level of nitrate and nitrite. On the evening before the examination day the subjects take a single dose of lithium carbonate 300 mg in order to measure lithium clearance. On the examination days subjects are receiving a two hour infusion of either placebo (isotonic sodium chloride) or sodium nitrite. During the two examination days each subject receives both treatments in random order.
Perspectives:
Increasing knowledge about the nitrite-NO system can contribute to changing the clinical practise of diagnostics and treatment of cardiovascular diseases.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sodium nitrite
Arm Type
Active Comparator
Arm Description
Sodium nitrite, 240 micrograms/kg/hour for 2 hours
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
Intervention Type
Drug
Intervention Name(s)
Sodium nitrite
Other Intervention Name(s)
NaNO2
Intervention Description
Sodium nitrite, 240 micrograms/kg/hour for 2 hours
Intervention Type
Drug
Intervention Name(s)
Sodium chloride
Other Intervention Name(s)
NaCl
Intervention Description
Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
Primary Outcome Measure Information:
Title
Fractional urinary sodium excretion (FENa)
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Peripheral (brachial) blood pressure
Description
Measured by oscillometric sphygmomanometer
Time Frame
1 day
Title
Central aortic systolic blood pressure (CASP)
Description
Measured by tonometric pulse wave analysis. Device BPro from HealthSTATS international, Singapore
Time Frame
1 day
Title
Plasma concentration of nitrite and nitrate (NOx)
Time Frame
1 day
Title
Urinary excretion of nitrite and nitrate (NOx)
Time Frame
1 day
Title
Glomerular filtration rate
Time Frame
1 day
Title
Proximal sodium transport (Estimated by lithium clearance)
Description
Estimated by lithium clearance
Time Frame
1 day
Title
Free water clearance
Time Frame
1 day
Title
Urinary excretion of cyclic guanosine monophosphate (cGMP)
Time Frame
1 day
Title
Urinary excretion of epithelial sodium channels (ENaC)
Time Frame
1 day
Title
Urinary excretion of aquaporin 2 water channels (AQP2)
Time Frame
1 day
Title
Plasma concentration of renin (PRC)
Time Frame
1 day
Title
Plasma concentration of angiotensin II (ANG2)
Time Frame
1 day
Title
Plasma concentration of aldosterone
Time Frame
1 day
Title
Plasma concentration of atrial natriuretic peptide (ANP)
Time Frame
1 day
Title
Plasma concentration of brain natriuretic peptide (BNP)
Time Frame
1 day
Title
Plasma concentration of cyclic guanosine monophosphate (cGMP)
Time Frame
1 day
Title
Plasma concentration of endothelin
Time Frame
1 day
Title
Plasma concentration of vasopressin (AVP, ADH)
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (subjects with hypertension):
BMI 18.5-30.0
Ambulatory daytime blood pressure >135 mmHg systolic and/or >85 mmHg diastolic
Women of childbearing potential must use safe contraception
Exclusion Criteria (subjects with hypertension):
Tobacco smoking, medicine or substance abuse
Weekly consumption of more than 14 units (12 g alcohol per unit) for women and 21 units for men
Pregnancy or nursing
Neoplasia
Clinically significant heart, lung, liver, kidney, metabolic or neurologic disease
Albuminuria > 300 mg/L
Renography with signs of renal artery stenosis or hydronephrosis
Clinically signs of secondary hypertension
Clinically significant hypokalemia
Clinically significant anemia
Estimated glomerular filtration rate (eGFR) < 60 ml/min
Clinically significant findings in screening blood samples, urine sample or ECG
Persistent office blood pressure > 170/105 mmHg on the maximum dose of amlodipine (10 mg daily)
Unacceptable symptoms of elevated blood pressure
Unacceptable side effects of amlodipine
Inclusion Criteria (healthy normotensive subjects):
BMI 18.5-30.0
Women of childbearing potential must use safe contraception
Exclusion Criteria (healthy normotensive subjects):
Tobacco smoking, medicine or substance abuse
Weekly consumption of more than 14 units (12 g alcohol per unit) for women and 21 units for men
Medical treatment 2 weeks prior to each examination day, except for contraception
Pregnancy or nursing
Neoplasia
Clinically significant heart, lung, liver, kidney, metabolic or neurologic disease
Clinically significant albuminuria
Clinically significant anemia
Estimated glomerular filtration rate (eGFR) < 60 ml/min
Clinically significant findings in screening blood samples, urine sample or ECG
Ambulatory daytime blood pressure >135/85 mmHg
Blood donation within 1 month of the first examination day
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeppe B Rosenbaek, MD
Phone
+4578436585
Email
jepros@rm.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Erling B Pedersen, MD, DMSc
Phone
+4578436840
Email
ebp@dadlnet.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erling B Pedersen, MD, DMSc
Organizational Affiliation
Holstebro Regional Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Medical Research and Medicine, Holstebro Regional Hospital
City
Holstebro
ZIP/Postal Code
7500
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeppe B Rosenbaek, MD
Phone
+4578436585
Email
jepros@rm.dk
First Name & Middle Initial & Last Name & Degree
Jeppe B Rosenbaek, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
29065098
Citation
Rosenbaek JB, Hornstrup BG, Jorgensen AN, Mortensen J, Pedersen EB, Bech JN. Effects of sodium nitrite on renal function and blood pressure in hypertensive vs. healthy study participants: a randomized, placebo-controlled, crossover study. J Hypertens. 2018 Mar;36(3):666-679. doi: 10.1097/HJH.0000000000001598.
Results Reference
derived
Learn more about this trial
The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects
We'll reach out to this number within 24 hrs